- Home
- NPCE vs AOMR Comparison
NPCE vs AOMR Comparison
Compare NPCE & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- AOMR
- Stock Information
- Founded
- NPCE 1997
- AOMR 2018
- Country
- NPCE United States
- AOMR United States
- Employees
- NPCE N/A
- AOMR N/A
- Industry
- NPCE Medical Specialities
- AOMR Real Estate Investment Trusts
- Sector
- NPCE Health Care
- AOMR Real Estate
- Exchange
- NPCE Nasdaq
- AOMR Nasdaq
- Market Cap
- NPCE 217.5M
- AOMR 240.9M
- IPO Year
- NPCE 2021
- AOMR 2021
- Fundamental
- Price
- NPCE $8.98
- AOMR $9.81
- Analyst Decision
- NPCE Buy
- AOMR Buy
- Analyst Count
- NPCE 7
- AOMR 6
- Target Price
- NPCE $15.71
- AOMR $12.10
- AVG Volume (30 Days)
- NPCE 120.5K
- AOMR 119.1K
- Earning Date
- NPCE 11-12-2024
- AOMR 11-06-2024
- Dividend Yield
- NPCE N/A
- AOMR 13.06%
- EPS Growth
- NPCE N/A
- AOMR N/A
- EPS
- NPCE N/A
- AOMR 2.91
- Revenue
- NPCE $76,452,000.00
- AOMR $94,441,000.00
- Revenue This Year
- NPCE $20.21
- AOMR N/A
- Revenue Next Year
- NPCE $15.04
- AOMR $29.25
- P/E Ratio
- NPCE N/A
- AOMR $3.37
- Revenue Growth
- NPCE 27.00
- AOMR 455.18
- 52 Week Low
- NPCE $5.45
- AOMR $8.88
- 52 Week High
- NPCE $18.15
- AOMR $13.32
- Technical
- Relative Strength Index (RSI)
- NPCE 66.14
- AOMR 52.63
- Support Level
- NPCE $6.63
- AOMR $9.80
- Resistance Level
- NPCE $10.42
- AOMR $10.11
- Average True Range (ATR)
- NPCE 0.83
- AOMR 0.22
- MACD
- NPCE 0.30
- AOMR 0.11
- Stochastic Oscillator
- NPCE 67.20
- AOMR 75.20
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.